FDA Commissioner Marty Makary resigned recently amid political pressure. Key leadership departures left top drug and biologics oversight positions to temporary appointees. Analysts warn the resulting leadership vacuum may cause regulatory unpredictability and delays.
The Nasdaq Biotechnology Index rose immediately after Makary’s departure. Market sentiment for the sector continues to improve behind strong merger and acquisition activity. Investors previously characterized Makary as an industry-unfriendly regulator. Shares of uniQure and Replimune gained following their public disagreements with the agency.